|
|
|
|
|
Legal status
Patent lapsed (non-payment of fees)
| (51) | INT.CL. | C07K 16/28 | (2006.01) |
| A61K 39/395 | (2006.01) |
| (11) | Number of the document | 2766395 |
| (13) | Kind of document | T |
| (96) | European patent application number | 12775423.2 |
| Date of filing the European patent application | 2012-10-12 | |
| (97) | Date of publication of the European application | 2014-08-20 |
| (45) | Date of publication and mention of the grant of the patent | 2019-11-20 |
| (46) | Date of publication of the claims translation | 2020-03-25 |
| (86) | Number | PCT/US2012/059977 |
| Date | 2012-10-12 |
| (87) | Number | WO 2013/056068 |
| Date | 2013-04-18 |
| (30) | Number | Date | Country code |
| 201161546800 P | 2011-10-13 | US | |
| 201261655110 P | 2012-06-04 | US |
| (72) |
NADLER, Steven G., US
TAMURA, James K., US
PRICE, Laura, US
REHFUSS, Robert P., US
SUCHARD, Suzanne J., US
SURI, Anish, US
BRYSON, James William, US
YAMNIUK, Aaron, US
GRANT, Steven, GB
IGNATOVICH, Olga, GB
DREW, Philip, GB
|
| (73) |
Domantis Limited,
980 Great West Road, Brentford, Middlesex TW8 9GS,
GB
Bristol-Myers Squibb Company, Route 206 and Province Line Road, Princeton, NJ 08543, US |
| (74) |
Jurga PETNIŪNAITĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
| (54) | Antikūno polipeptidai, kaip CD40L antagonistai |
| ANTIBODY POLYPEPTIDES THAT ANTAGONIZE CD40L |
| Payment date | Validity (years) | Amount | |
| 2020-09-24 | 9 | 208.00 EUR |
| Patent lapsed (non-payment of fees) | ||
| Invalidation date | 2021-10-12 |